Table 2.
Frequency of HSRsa in patients treated IV with different reactogenic drugs
| Reaction rate | Drugs | Drug Type |
|---|---|---|
| Very high P > 10% | Rituximab, infliximab | mAb |
| Doxil (Caelyx), AmB (AmBisome) | Liposome‐encapsulated | |
| Taxanes (paclitaxel, docetaxel), platinum | Micellarized anticancer | |
| High 1% < P <10% | Natalizumab, cetuximab, trastuzumab, panitumumab, gentuzumab | mAb |
| Amphotec, Myocet, Amphocyl, DaunoXome, Abelcet, Visudyne | Liposome | |
| Penicillin | Antibiotic | |
| Platinum compounds (cisplatin, carboplatin), | Anticancer drugs | |
| Moderate 0.1 < P % <1 | Omalizumab | Monoclonal antibodies (mAbs) |
| Alemtuzumab | ||
| Trastuzumab | ||
| Cephalosporins/carbapenems, aztreonam, imipenem | Antibiotics | |
| Iodinated contrast agents (Ioxaglate, Iohexol, Iopamidol, Ioversol, Iopromide, Ioxilan) | Radiocontrast agents | |
| low 0.01 < P % <0.1 | Bevacizumab | mAb |
| Epipodophyllotoxins (teniposide, etoposide), asparaginase, procarbazine, doxorubicin, 6‐mercaptopurine | Anticancer drugs | |
| Acetaminophen (paracetamol), aspirin, ibuprofen | Anaesthetics, analgesics antalgics, antipyretics and non‐steroidal anti‐inflammatory drugs | |
| Phenytoin, carbamazepine phenobarbital sodium Lamotrigine, primidone diphenylhydantoin, sulfonamides (procainamide), sulfonylureas | Anticonvulsants (antiepileptics) | |
| Iodinated contrast agents (ioxaglate, iohexol, iopamidol, ioversol, iopromide, ioxilan, iodixanol, Gd‐GTPA | Contrast agents | |
| Venofer, Cosmofer, Ferinject, Monofer, Ferrlecit, Ferumoxytol | IV‐ironb | |
| Very low P < 0.01 | SonoVue | Contrast agents |
| Venofer, Cosmofer, Ferinject, Monofer, Ferrlecit, Ferumoxytol | IV‐ironb |
a
All types of reactions regardless of severity. Rates were obtained from individual box labels, public (internet) information or Summaries of Product Characteristics.
b
Data uncertain to select the exact category, P = prevalence.